Skip to main content
. 2018 Dec 19;6:152. doi: 10.1186/s40425-018-0474-z

Fig. 2.

Fig. 2

Kaplan-Meier analysis of overall survival in ipilimumab treated melanoma patients. Overall survival for patients with biomarker levels in the upper quartile (Q4) vs the lower quartiles (Q1 + Q2 + Q3) for PRO-C3, C1M, C3M and C4M, while for VICM it is the upper quartiles (Q3 + Q4) vs the lower quartiles (Q1 + Q2). A log-rank test was used to determine differences between the survival curves where a p-value of p < 0.05 was considered statistically significant